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ABSTRACT  21 
Epidemiological studies have indicated a positive association between the intake of foods 22 
rich in anthocyanins and the protection against cardiovascular diseases. Some authors have 23 
shown that anthocyanins are degraded by the gut microflora giving rise to the formation of 24 
other breakdown metabolites, which could also contribute to anthocyanin health effects. 25 
The objective of this study was to evaluate the effects of anthocyanins and their breakdown 26 
metabolites, protocatechuic, syringic, gallic, and vanillic acids, on different parameters 27 
involved in atherosclerosis, including inflammation, cell adhesion, chemotaxis, endothelial 28 
function, estrogenic/antiestrogenic activity and angiotensin-converting enzyme (ACE) 29 
inhibitory activity. From the assayed metabolites, only protocatechuic acid exhibited a 30 
slight inhibitory effect on NO production and TNF-α secretion in LPS-INF-γ-induced 31 
macrophages. Gallic acid caused a decrease in the secretion of MCP-1, ICAM-1 and 32 
VCAM-1 in endothelial cells. All anthocyanins showed an ACE inhibitory activity. 33 
Delphinidin-3-glucoside, pelargonidin-3-glucoside and gallic acid showed affinity for ERβ 34 
and pelargonidin and peonidin-3-glucosides for ERα. The current data suggest that 35 
anthocyanins and their breakdown metabolites may partly provide a protective effect 36 
against atherosclerosis that is multi-causal and involves different biochemical pathways. 37 
However, the concentrations of anthocyanins and their metabolites, as used in the present 38 
cell culture and in vitro assays mediating anti-inflammatory, anti-adhesive, anti- anti-39 
estrogenic, and angiotensin-converting enyzme inhibitory activities, were often manifold 40 
higher than those physiologically achievable. 41 
42 
INTRODUCTION 43 
Polyphenolic substances, such as anthocyanins, exert a great variety of physiological 44 
activities responsible for the health effects attributed to some foods, including a reduced 45 
risk of cardiovascular diseases. This is partly due to their anti-inflammatory properties 46 
(González-Gallego 2010; Landberg 2011; Rotelli 2003), antioxidant and free radical 47 
scavenging activities (García-Alonso 2009; Gray 1999; Kahkonen 2003; Matsumoto 2002; 48 
Tsuda 1994; Wang 1997), peroxidation inhibition (Tsuda 1996) and 49 
estrogenic/antiestrogenic activity (Cassidy 2003). It has been largely proven that the 50 
beneficial potential of polyphenols as part of a healthy diet can not be only explained by 51 
their antioxidant characteristics (Virgili 2008). 52 
One of the biological mechanisms by which flavonoids exhibit anti-inflammatory effects 53 
appears to be associated with the inhibition of nitric oxide (NO) production (Vallance 54 
2002). A critical step in both inflammation and atherosclerosis is the adhesion of circulating 55 
monocytes to vascular endothelial cells which involves vascular cell adhesion molecule-1 56 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Studies in vitro suggest that 57 
flavonoids participate in the prevention and attenuation of inflammatory diseases by 58 
decreasing ICAM-1 and VCAM-1 levels (Kwon 2005; Lotito 2006). In addition, dietary 59 
anthocyanins and hydroxycinnamic acids have been reported to reduce TNF-α-induced up-60 
regulation of various inflammatory mediators such as ICAM-1 or MCP-1. Therefore, the 61 
ability of polyphenols to mediate inflammatory processes is likely to contribute to their 62 
antiatherogenic properties. 63 
The effect of flavonoids on the arterial wall due to their estrogenic activity is well known. 64 
Flavonoids reduce the risk of cardiovascular diseases (Kris-Etherton 2002), decrease serum 65 
cholesterol, low-density lipoproteins (LDL) and triglyceride levels (Ricketts 2005), prevent 66 
osteoporosis (Dang 2005) and improve menopausal symptoms (McCann 2005). Notably, 67 
work has already shown that the estrogenic properties of wine flavonoids inlcuding 68 
anthocyanins are due, in part, to their ability to bind the estrogen receptor (Chalopin 2010; 69 
Schmitt 1996). 70 
In addition, flavonoids have been suggested to decrease cardiovascular risk by reducing 71 
levels of angiotensin II, a well-known proinflammatory mediator (Naruszewicz 2007). It 72 
has already been reported that some anthocyanin containing foods as well as delphinidin, 73 
inhibit ACE activity (Actis-Goretta 2006; Lacaille-Dubois 2001; Persson 2009). 74 
Anthocyanins intake in humans has been estimated to be between 3 and 215 mg/day (Chun 75 
2007; Frankel 1995; Pérez-Jimenez 2011; Wu 2006). Most studies have shown very low 76 
bioavailability of anthocyanins based only on the measurement in plasma or urine of the 77 
original anthocyanins and their conjugated metabolites, glucuronidated and sulphated 78 
anthocyanins (Manach 2005). More recently, it has been established that the intestinal 79 
microflora plays a key role in the metabolism of anthocyanins. After ingestion, 80 
anthocyanins can be hydrolysed by intestinal glucosidases, and the resulting aglycones are 81 
further metabolised in the large intestine to other breakdown metabolites such as 82 
protocatechuic, gallic, syringic and vanillic acids (Avila 2009; Forester 2008, Keppler 83 
2005; Vitaglione 2007). Moreover gallic acid has been determined in plasma after its 84 
ingestion at levels as high as 1.8 µmo/L in its original form and at 2.2 µmo/L as its 85 
derivative 4-O-methylgallic acid (Shahrzad 1998, 2001). Therefore, metabolites produced 86 
by the intestinal microflora could account partly for the health benefits associated with 87 
anthocyanin consumption in humans. 88 
The aim of this study was to further elucidate the potential mechanisms by which 89 
anthocyanins and their metabolites reduce the initial stages of atherosclerosis. Specifically, 90 
we have studied the effect of anthocyanins and their metabolites on 1) NO production and 91 
TNF-α secretion in macrophages, and 2) ICAM-1, VCAM-1 and MCP-1 secretion in 92 
endothelial cells. The ACE inhibitory activity of anthocyanins and their metabolites was 93 
also measured. Finally, their ERα and ERβ binding ability was measured. Docking studies 94 
helped to rationalize selectivity on ERs. 95 
 96 
MATERIALS AND METHODS 97 
 98 
Chemicals 99 
Cyanidin-3-O-glucoside, pelargonidin-3-O-glucoside, malvidin-3-O-glucoside, 100 
delphinidin-3-O-glucoside and peonidin-3-O-glucoside were purchased from Extrasynthese 101 
(Lyon, France). Acetate buffer saline, neutral red, griess reagent, crystal violet, LPS 102 
(lipopolisaccharide), human recombinant TNF-α, mouse recombinant IFN-γ, 17-β-103 
estradiol, PBS, Tween-20, BSA, ACE (peptidyl-dipeptidase A, EC 3.4.15.1) and the 104 
phenolic acids: gallic, syringic, protocatechuic, vanillic, sinapic, homogentisic, 4-105 
hidroxybenzoic, phloroglucinol, 3-(2´,5´-dimethoxybenzoil) propionic (DMB propionic), 106 
coumaric and caffeic acids were purchased from Sigma-Aldrich Química S.A. (Madrid, 107 
Spain). Ethanol 99%, glacial acetic acid and dimethyl sulfoxide (DMSO) were obtained 108 
from Panreac (Barcelona, Spain). Sodium dodecyl sulphate (SDS) was acquired from 109 
Fisher (Madrid, Spain). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum 110 
(FBS), penicillin/streptomycin, trypsin, L-glutamine and nonessential amino acids were 111 
purchased from Lonza (Barcelona, Spain). Estradiol [2,4,6,7,16,17-
3
H(N)] and scintillation 112 
counting liquid (Optifase HiSafe2) were obtained from Perkin-Elmer (Salem, MA). 113 
Estrogen receptors α and β (human recombinant produced in insect cells) were purchased 114 
from Invitrogen (Barcelona, Spain). 115 
 116 
Macrophages 117 
RAW 264.7 cells, a murine monocyte macrophage cell line, were maintained at 37 °C in 5 118 
% CO2 according to standard protocols (Rimbach 2000). The medium consisted of DMEM 119 
with 4.5 g/L glucose and L-glutamine supplemented with 10% FBS and 1% 120 
penicillin/streptomycin (5000 U/mL). For experiments, cells were harvested with trypsin-121 
EDTA and macrophages were plated in 24-well plates at a density of 5x10
4
 in 0.5 mL of 122 
medium for the cytotoxicity test or in 6-well plates at a density of 2x10
5 
in 2 mL of 123 
medium, for nitrite and TNF-α measurement. Finally, cells were cultured for 72 h until they 124 
reached 80% confluence. Cells in 6-well plates were treated with gallic, vanillic, 125 
protocatechuic and syringic acids in a range of concentrations between 0.01-500 μM or 126 
DMSO (< 0.1%) as follows; four different treatments were performed. (A) Cells were pre-127 
treated for 3 h with the different compounds, washed twice with PBS and then stimulated 128 
with 1 μg/ml LPS for 24 h. (B) Cells were pre-treated with the different compounds for 3 h, 129 
washed twice with PBS and then stimulated with 1μg/mL LPS plus 1000 U/mL IFN-γ for 130 
24 h. (C) Cells were co-incubated with the different compounds at 200 μM together with 1 131 
μg/ml LPS for 24 h. (D) Cells were co-incubated with the different compounds at 200 μM 132 
and with 1 μg/ml LPS plus 1000 U/ml IFN-γ simultaneously for 24 h. For all these 133 
experiments, control cells were grown under identical conditions but were not exposed to 134 
the test compound or LPS/IFN-γ. For the cytotoxic assay, cells were treated with all 135 
compounds at the maximal concentration used in the NO production assay. 136 
 137 
Endothelial cells 138 
EA.hy 926 cells, a cell line derived from human umbilical vein endothelial cells (HUVEC), 139 
were a generous gift from Prof. C-J. S. Edgell, University of North Carolina at Chapel Hill. 140 
EA·hy 926 cells were generated by fusion of human umbilical vein endothelial cells 141 
(HUVEC) with the human lung carcinoma cell line A549 and have been extensively used 142 
as a cell model for endothelial function (Fuchs 2005) Cells were grown in DMEM medium 143 
containing 4.5 g/L glucose and L-glutamine and supplemented with 10% FBS and 1% 144 
penicillin/streptomycin (5000 U/mL). Cells were harvested with trypsin-EDTA and seeded 145 
in 0.5 mL of medium in 24-well plates or 2 mL of medium in 6-well plates and cultured 146 
until they reached 80% confluence. After pre-treatment in 6-well plates with 10 and 100 147 
µM of gallic, vanillic, protocatechuic and syringic acids for 16 h, cells were stimulated with 148 
10 ng/mL TNF-α for 6 h. 149 
 150 
Estrogen receptor (ER) competitive binding assay 151 
The binding activity of anthocyanins and acids to human ER was determined using a 152 
radioactivity assay based on the ability of the different compounds to compete with 3H-153 
labeled estradiol for the estrogen receptor. For the ERβ- and ERα-binding assay, the 154 
corresponding pure estrogen receptor was used at 2.4 nM together with 5nM tritium-155 
labelled estradiol ([2,4,6,7,16,17-3H]estradiol). Unlabeled estradiol, anthocyanins and acids 156 
were prepared in DMSO (<0.5%) and diluted in PBS-T (PBS + 0.15% Tween20) including 157 
receptors and Estradiol-H
3
*. Briefly, the same volume of each compound, Estradiol-H
3
* 158 
and receptor were mixed in a final volume of 150 μL, thus the different compounds were 159 
tested at a concentration ranging from 1 to 200 μM. The mixture was incubated for 4 h at 160 
23 ºC to allow receptor binding. Afterwards, 50 μL of charcoal (charcoal 0.1 g/ml and BSA 161 
0.02 g/mL) was added and the samples kept on ice for 15 minutes before being centrifuged 162 
at 6000 x g for 5 min to remove the non-bound Estradiol-H
3
*. An aliquot of this 163 
supernatant (150 μL) was added to 4 mL of scintillation counting liquid. The bound [3H]-164 
estradiol was measured in a WinSpectral 1414 Liquid Scintillation Counter (Beckman, LS 165 
6500). Three independent experiments containing three replicates were performed for each 166 
compound tested. Results are expressed as the percentage of specific binding of [3H] 167 
estradiol to ER versus log of competitor concentration. IC50 values represent the 168 
concentration of test compound required to displace 50% [3H] estradiol from the receptor. 169 
IC50 values were determined by nonlinear regression fitting of experimental data to a 170 
sigmoid equation. 171 
 172 
Docking studies 173 
Geometries of compounds X-Y were first optimized using the ab initio quantum chemistry 174 
program Gaussian 03 (2004) and the B3LYP/3-21G* basis set. As macromolecules, the X-175 
ray structures of estrogen receptor complexes with genistein were chosen (PDB codes: 1x7r 176 
for ERα and 1x7j for ERβ). Crystallographic water molecule close to Arg394 (ERβ 177 
Arg346) and Glu353 (ERβ Glu305) were kept as they were considered to be part of the 178 
binding site. Different conformers of the ligands were docked using the Lamarckian genetic 179 
algorithm implemented in AutoDock 3.1 (Morris 1998) by randomly changing the torsion 180 
angles and overall orientation of the molecule. A volume for exploration was defined in the 181 
shape of a three-dimensional grid (80 × 80 × 90 Å
3
) with a spacing of 0.375 Å that enclosed 182 
the binding site, and included the residues that are known to be crucial for activity. At each 183 
grid point, the receptor’s atomic affinity potentials for carbon, aromatic carbon, oxygen, 184 
nitrogen, sulphur, and hydrogen atoms were precalculated for rapid intra- and 185 
intermolecular energy evaluation of the docking solutions for each ligand. The original 186 
Lennard-Jonnes and hydrogen-bonding potentials provided by the program were used. The 187 
parameters for the docking using the LGA were identical for all docking jobs. After 188 
docking, the 100 solutions were clustered in groups with root mean square deviations less 189 
than 1.0 Å. The clusters were ranked by the lowest energy representative of each cluster.  190 
 191 
Cell viability 192 
The uptake of neutral red dye was used to assess cell viability as described previously 193 
(Valacchi 2001). Macrophages and Ea.hy 926 cells were pre-treated in 24-well plates with 194 
the different test compounds for 24 h. After incubation, the culture medium was removed 195 
and replaced with fresh medium containing 50 μg/mL of neutral red. Following incubation 196 
for 2 h at 37 ºC, the medium was removed and the cells extracted using a solution 197 
comprising 50:49:1 (v/v/v) ethanol, water, and glacial acetic acid. Absorbance at 540 nm 198 
was recorded using a microplate reader (Power Wave XS, BIOTEK). For all cell culture 199 
experiments, compounds were dissolved in DMSO. The final DMSO concentration in the 200 
cell culture medium was 0.1% (v/v) or less. Pre-treatment of RAW 264·7 macrophages 201 
with up to 500 μM and treatment of Ea.hy 926 with up to 100 μM of any of the assayed 202 
compounds did not affect cell viability.  203 
 204 
NO Production 205 
NO production was assessed by measurement of nitrite concentration (NO2-) in the medium 206 
using the Griess reaction (Wang 2002b). Supernatants of cultured macrophages were 207 
collected and deproteinized with 0.3 M NaOH and 0.3 M ZnSO4. An equal volume of the 208 
Griess reagent (1% sulfanilamide/0.1% N-(1-naphthyl)ethylenediamine 209 
dihydrochloride/2.5% H3PO4) and the deproteinized samples were incubated for 10 min at 210 
room temperature protected from light. The nitrite concentration was determined by 211 
measuring the absorbance at 548 nm against a standard curve for sodium nitrite (Park 212 
2000). 213 
 214 
TNF-α Secretion in RAW 264.7 macrophages 215 
Supernatants from RAW 264.7 macrophages were collected for TNF-α secretion 216 
measurements as described above for NO production measurements. Upon collection, 217 
samples were centrifuged at 15700 x g for 10 min and the supernatants kept at -80 ºC until 218 
analysis. TNF-α secretion was measured using a commercially available enzyme-linked 219 
immunosorbent assay ELISA kit (Mouse TNF-α immunoassay, eBioscence). 220 
 221 
Secretion of monocyte chemoattractant protein 1 (MCP-1), intercellular adhesion 222 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) by EA.hy 926 223 
cells 224 
Upon collection of the supernatant from Ea.hy 926 cells, samples were centrifuged at 225 
15700 x g for 10 min and the supernatants were kept at -80 °C until analysis. The secretion 226 
of MCP-1, ICAM-1 and VCAM-1 by Ea.hy 926 cells were measured using commercially 227 
available ELISA kits (Diaclone, Bionova scientific). 228 
 229 
Determination of ACE-Inhibitory Activity 230 
ACE-inhibitory activity was measured by fluorescence using the method of Sentandreu and 231 
Toldrá (2006) with some modifications. Briefly, ACE (peptidyl-dipeptidase A, EC 232 
3.4.15.1) working solution was diluted with 0.15 M Tris buffer (pH 8.3) containing 0.1 µM 233 
ZnCl2 with 0.04 U/mL of enzyme in the final reaction solution. A total of 40 µL of this 234 
working solution (or distilled water for the blank) was added to each microtiter-plate well, 235 
with another 40 µL of distilled water for the blank (B) or 40 µL control (C) or 40 µL 236 
samples (S). The enzyme reaction was started by adding 160 μL of 0.45 mM o-Abz-Gly-p-237 
Phe(NO2)-Pro-OH (Bachem Feinchemikalien, Bubendorf, Switzerland) dissolved in 150 238 
mM Tris-base buffer (pH 8.3), containing 1.125 M NaCl, and the mixture was incubated at 239 
37 ºC. The fluorescence generated was measured at 30 min using a multiscan microplate 240 
fluorimeter (FLUOstar optima, BMG Labtech, Offeuburg, Germany). 96-well microplates 241 
(Porvair, Leatherhead, UK) were used. Excitation and emission wavelengths were 350 and 242 
420 nm, respectively. The software used to process the data was FLUOstar control (version 243 
1.32 R2, BMG Labtech). 244 
The ACE-inhibitory activity was evaluated in 11 phenolic acids: gallic, protocatechuic, 245 
syringic, vanillic, synapic, homogentisic, hydroxybenzoic, phloroglucinol, coumaric, 246 
caffeic and DMB propionic acid; and five anthocyanins: cyanidin-3-O-glucoside, malvidin-247 
3-O-glucoside, delphinidin-3-O-glucoside, peonidin-3-O-glucoside and pelargonidin-3-O-248 
glucoside. All samples were diluted in distilled water or ethanol-water 30/70 (v/v). 249 
The activity of each sample was tested in triplicate. Inhibitory activity was expressed as the 250 
concentration required to inhibit the original ACE activity by 50% (IC50). The formula 251 
applied to calculate the percentage of ACE-inhibitory activity was: 100 _ (C _ S)/(C _ B), 252 
where C is the fluorescence of ACE with o-Abz-Gly-p-Phe(NO2)-Pro-OH (fluorescence 253 
substrate) and without inhibitor, S is the fluorescence of ACE with o-Abz-Gly-p-254 
Phe(NO2)-Pro-OH  and with sample as inhibitor, and B is the fluorescence of the 255 
fluorescent substrate o-Abz-Gly-p-Phe(NO2)-Pro-OH. This parameter was plotted vs. 256 
sample concentration and non-linear logarithmic adjustment was performed as indicated by 257 
Quirós et al. (2007) to estimate IC50. 258 
 259 
Statistical analysis 260 
The results were reported as means ± standard deviation (SD) of at least three 261 
measurements or two in the case of ICAM-1, VCAM-1 and MCP-1, each performed in 262 
triplicate. One way analysis of variance (ANOVA) was used to compare the means, and the 263 
least significant difference (LSD) test showed the values statistically different. Differences 264 
were considered significant at P < 0.05. All statistical analyses were performed with 265 
Statgraphics Plus 5.1 (Statistical Graphics Corporation, Inc., Rockville, MD, USA). 266 
 267 
268 
RESULTS AND DISCUSSION 269 
 270 
Effect of phenolic acids on NO production and TNF-α secretion in LPS and LPS/IFN-271 
γ-stimulated macrophages 272 
Untreated macrophages did not produce detectable amounts of NO after the 24 hours 273 
incubation, but stimulation of macrophages with LPS increased NO production 274 
significantly (62.9 ± 20.2 NO nmol/mg protein). A synergistic effect was observed when 275 
IFN-γ was added simultaneously with LPS such that NO production was further increased 276 
(100.1 ± 9.0 nmol/mg protein). In the present study, gallic, vanillic and syringic acids did 277 
not inhibit NO production in activated macrophages. Protocatechuic acid slightly but 278 
significantly inhibited NO production in a dose-dependent manner between 0 and 100 μM, 279 
reaching an inhibition higher than 25% at 100 μM compared to LPS-treated control and by 280 
13% at 100 μM compared to LPS + IFN-γ-treated control (Table 1). 281 
When we co-treated macrophages with protocatechuic acid (10 μM) and LPS 282 
simultaneously, we found a 20% reduction in the NO content of the media despite 283 
observing no significant reduction when cells were pre-treated with 10 μM protocatechuic 284 
acid 3 hours prior to LPS stimulation. In addition, co-incubation of macrophages with 10 285 
μM protocatechuic acid together with LPS+IFN-γ, caused a larger inhibition of NO 286 
production (29%) compared to pre-treatment with 10 μM protocatechuic acid before 287 
cytokine stimulation (Table 2). This enhanced inhibition of NO production seen with co-288 
incubation compared to with pre-treatment might be a result of a direct chemical interaction 289 
between the protocatechuic acid and the stimuli used. 290 
Earlier studies have shown that the anti-inflammatory action of flavonoids is mediated via 291 
their inhibition of iNOS protein and mRNA expression as well as their inhibition of nuclear 292 
factor kB (NF-kB) and STAT-1 activation which are involved in the expression of several 293 
inflammatory genes (Chen 2005; Hämäläinen 1999).  294 
We next assessed the effect of anthocyanin metabolites on TNF-α secretion. We found that 295 
exposure of macrophages to LPS led to TNF-α secretion (3.0 ± 0.1 ng TNF-α/mg protein), 296 
and that exposure to both LPS and IFN-γ together induced a synergistic effect on TNF-α 297 
secretion (11.4 ± 1.1 ng TNF-α/mg protein). Similar to the results obtained for NO 298 
production, we found that pre-treatment of LPS-stimulated cells with protocatechuic acid at 299 
concentrations higher than 10 μM caused a reduction in TNF-α secretion, with a significant 300 
inhibition at 100 μM protocatechuic acid of 39 %. For cells treated with LPS+IFN-γ 301 
together, a low but significant inhibition of TNF-α secretion was observed only by 302 
protocatechuic acid at 50 μM and 100 μM (11.1% and 21.5%, respectively). Co-incubation 303 
with the other phenolic acids and stimulus did not affect TNF-α secretion. No effect on 304 
TNF-α was shown for any of the other polyphenols assayed, vanillic, protocatechuic and 305 
syringic acids in our experimental conditions. 306 
Monocyte-derived macrophages are the principal inflammatory cells in atheromas. Their 307 
activation is crucial to the progression of multiple inflammatory diseases such as septic 308 
shock, chronic inflammation and atherosclerosis, via the release of inflammatory and 309 
cytotoxic mediators like cytokines or NO (Tamir 1996). In the present study, we have 310 
shown that exposing macrophages to LPS and IFN-γ simultaneously induces a synergistic 311 
effect in terms of NO production as well as TNF- α secretion, in accordance with other 312 
authors (Orlicek 1996). 313 
Studies in the literature investigating the effects of anthocyanins on NO production and 314 
TNF-α secretion are controversial. García-Alonso et al. (2004) did not find an effect of 315 
anthocyanins on NO production or TNF-α secretion when used to pre-treat RAW 264.7 316 
macrophages 24 hours prior incubation with LPS. In contrast, Hämäläinen et al. (1999) 317 
observed an inhibition of NO production as well as of iNOS protein and mRNA expression 318 
with pelargonidin treatment of macrophages exposed to an inflammatory stimulus (LPS). 319 
Also, Wang et al. (2002a) demonstrated an inhibitory effect of anthocyanins on LPS-320 
induced NO production in macrophages. 321 
Recently Long et al. (2010) have shown that some flavonoids may increase the levels of hydrogen 322 
peroxide in the cell culture medium, thereby possibly affecting also some of the parameters that 323 
have been measured within the present. This increase in H2O2 in response to the flavonoid treatment 324 
may be due to a rapid degradation of some flavonoids at neutral pH and 37°C. This has been 325 
reported for anthocyanins such as delphinidin chloride, an extremely unstable compound, and may 326 
have also occurred in terms of its 3-glucoside (Avila 2009). Furthermore Long et al. (2010) 327 
demonstrated that different cell culture media may have different effects on H2O2 production for the 328 
same polyphenol test compound. Thus compound instability and generation of H2O2 should be 329 
taken into account in interpreting effects of anthocyandins in cultured cells (Long et al 2010). 330 
Related to our findings, Yan et al. (2004) demonstrated that protocatechuic acid isopropyl 331 
ester reduced plasma TNF-α, NO and hepatic malondialdehyde levels in a mouse model of 332 
septic shock induced by LPS and D-galactosamine. In our study, protocatechuic acid 333 
exhibited a protective effect in LPS/INF-γ-induced macrophages by inhibiting the 334 
overproduction of inflammatory mediators, namely NO and TNF-α.  335 
In our work, and in accordance with other studies (Terra 2007), we compared the ability of 336 
anthocyanin metabolites to inhibit NO production in macrophages using four different 337 
treatment protocols (preincubation with polyphenols and activation with LPS alone or LPS 338 
plus INF-γ, and co-incubation with polyphenols and LPS alone or LPS plus INF-γ). When 339 
macrophages were co-incubated simultaneously with the test compound and stimulus, 340 
protocatechuic acid was found to exhibit the strongest inhibition of NO secretion. In this 341 
case, we propose that protocatechuic acid acts by scavenging NO radicals or by a direct 342 
interaction with LPS or IFN-γ. However, the high level of inhibition of NO production and 343 
TNF-α secretion observed in cells pre-incubated with protocatechuic acid before LPS 344 
activation may be due to different mechanisms of action of flavonoids, as described above.  345 
It needs to be considered that that the concentrations of protocatechuic acid which inhibited NO 346 
secretion in our cell culture experiments were very high and rather not in the physiological range. 347 
Protocatechuic acid has been detected in plasma (human and rat) at concentrations that are around 348 
200 nmol/L, which is 100 fold higher than the original anthocyanins concentration in plasma 349 
(between 1 and 10 nmol/L) (Caccetta 2000) but still very much lower than the concentrations used 350 
in our cell culture experiments. 351 
Our results suggest that foods rich in polyphenols, which may lead to elevated levels of 352 
protocatechuic acid in plasma, could be beneficial in he prevention of inflammatory 353 
diseases since they reduce the production of the cytotoxic oxidative stress mediator NO as 354 
well as the production of TNF-α, a crucial cytokine for the synergistic induction of NO 355 
synthesis. 356 
 357 
Effect of phenolic acids on MCP-1, ICAM-1 and VCAM-1 secretion in endothelial 358 
cells 359 
Untreated EA.hy 926cells released very low levels of MCP-1, ICAM-1 and VCAM-1 into 360 
the media. However, when treated with TNF-α (10 ng/ml) to mimic pro-inflammatory 361 
conditions, there was a marked increase in the secretion of MCP-1 (2.2 ng/ml ± 0.3), 362 
ICAM-1 (0.9 ng/ml ± 0.1) and VCAM-1 (4.9 ng/ml ± 3.6). Pre-treatment with gallic acid 363 
elicited a statistically significant dose-dependent decrease in the secretion of MCP-1, 364 
ICAM-1 and VCAM-1 at concentrations ≥ 10 μM compared with activated control cells 365 
(Table 3). None of the other polyphenols assayed, vanillic, protocatechuic and syringic 366 
acids, showed any effect on the secreted levels of MCP-1, ICAM-1 and VCAM-1 in our 367 
experimental conditions. 368 
Many epidemiological studies have reported that moderate wine consumption exerts a 369 
protective effect against cardiovascular diseases (Estruch 2000; Gronbaek 2000). In 370 
addition, clinical studies have demonstrated that daily intake of wine reduces monocyte 371 
adhesion and circulating markers of inflammation (Badia 2004; Estruch 2004). Moreover, 372 
Sacanella et al. (2007), showed a more potent effect of red wine versus white wine, 373 
possibly due to its higher anthocyanin content. A suppression of NF-kB in white blood cells 374 
by red wine was suggested to play a key role in its anti-inflammatory effects (Blanco-Colio 375 
2000). In accordance with these studies, we observed a significant reduction in MCP-1, 376 
ICAM-1 and VCAM-1 levels when endothelial cells were pre-treated with gallic acid. This 377 
reduction was especially marked in the case of VCAM-1. Previous studies have reported 378 
that endothelial cells in human atherosclerotic lesions increase cell adhesion molecules 379 
(CAMs) and MCP-1. Therefore, gallic acid might be an effective protector against 380 
monocyte recruitment in inflammatory vessels and may prove useful in the prevention of 381 
atherosclerotic lesion development due, in part, to a decrease in MCP-1 which promotes 382 
monocytes infiltration into the arterial wall. 383 
 384 
Determination of ACE inhibitory activity 385 
We assessed the ACE inhibitory activity of the potentially bioactive phenolic acids and 386 
anthocyanins by measuring their IC50 values (the concentration required to inhibit the 387 
original ACE activity by 50%). The ACE inhibitor activity was first determined for all the test 388 
compounds at a concentration of 500 μM and only those ones showing a percentage of inhibition 389 
higher than 50% where used to calculate their corresponding IC50 vaules. The ACE inhibotry 390 
activity was then tested at 6 different concentrations between 1 and 500 μM in order to obtain a 391 
dose-response curve. Data are summarized in Table 4. The anthocyanins inhibited ACE 392 
activity in a dose-dependent manner, with delphinidin-3-glucoside being the most active 393 
(IC50 = 65.4 μM) followed closely by cyanidin-3-O-glucoside (IC50 = 70.8 μM), 394 
pelargonidin-3-O-glucoside (IC50 = 77.7 μM), malvidin-3-O-glucoside (IC50 = 83.9 μM) 395 
and peonidin-3-O-glucoside (IC50 = 104.6 μM). This observation suggests that the presence 396 
of a hydroxyl group, as well as the O-glycosides structure, enhances the inhibitory activity. 397 
We found that of all of the phenolic acids, only caffeic, gallic and coumaric acids exhibited 398 
a marginal ACE- inhibitory activity with IC50 values of 157.3 μM, 332.4 μM and 504.2 399 
μM, respectively. All the other assayed compounds, protocatechuic, syringic, vanillic, 400 
synapic, homogentisic, hydroxybenzoic, phloroglucinol, and DMB propionic acid showed 401 
an inhibition of ACE lower than 50% for a 500 μM concentration. 402 
The in vitro ACE-inhibitory activity of flavonoids is due to the generation of chelate 403 
complexes with the zinc atom within the active centre of ACE (García-Saura 2005). Free 404 
hydroxyl groups of phenolic compounds are suggested to be important structural moieties 405 
to chelate the zinc ions, thus inactivating the ACE activity. It may therefore be the hydroxyl 406 
groups within the anthocyanins and phenolics acids that are responsible for their ACE 407 
inhibitory activity. In fact, ACE inhibitory activity has been already demonstrated in some 408 
compounds derived from plants such as flavonoids (Wille 2001), terpenoids (Morigiwa 409 
1986), peptides (Kinoshita 1993) and procyanidins (Wagner 1992). 410 
It is therefore likely that anthocyanins and their breakdown metabolites, phenolic acids, 411 
have hypotensive and protective effects on endothelial function due, at least in part, to their 412 
ACE inhibitory effect since angiotensin II regulates arterial blood pressure, adhesion 413 
molecule expression, cytokines, chemokines and growth factors within the arterial wall.  414 
 415 
Relative affinity for ERα and ERβ 416 
The first step to determine the estrogenic activity of a given compound is to measure the 417 
binding of this potential ligand to the estrogenic receptor. In general, the affinity of 418 
flavonoids to bind to ERα and β is lower than that of 17-β-estradiol. However some studies 419 
have confirmed that genistein, daidzein and equol have a good affinity for ER, especially 420 
for ERβ (Mueller 2004). 421 
The ER binding affinity of anthocyanins and their metabolites was determined in a 422 
radioactivity assay by measuring their ability to compete with 17-β-estradiol for the ER. 423 
Table 5 summarizes the IC50 values obtained (concentration required to inhibit binding of 424 
[
3
H]-estradiol to the corresponding ER by 50%). Pelargonidin-3-glucoside showed affinity 425 
for both receptors, with a relatively higher affinity for ERα (61.3 μM ± 0.7) than for ERβ 426 
(93.0 μM ± 0.8), whereas peonidin-3-glucoside only demonstrated affinity for ERα (64.4 427 
μM ± 0.9) and delphinidin-3-glucoside only reasonable affinity for ERß (63.2 μM ± 0.8). 428 
Among the phenolic acid metabolites assayed, gallic acid showed affinity for ERß (100.3 429 
μM ± 0.9) but did not show affinity for ERα.  430 
It is interesting to note that delphinidin-3-glucoside and gallic acid, with similar structural 431 
features in the hydroxylation pattern of their B ring, showed affinity for ERβ, but not for 432 
ERα. Moreover, delphinidin-3-glucoside demonstrated a binding affinity for ERβ that is 433 
approximately 2-fold higher than that of gallic acid. These results are in accordance with 434 
those obtained in the molecular modeling studies and could be explained by the hypotheses 435 
that two molecules of gallic acid are able to bind to the ER and display 436 
estrogenic/antiestrogenic activities. 437 
All other test compounds did not show any affinity for the ER at the concentrations tested.  438 
Schmitt and Stopper (2001) have reported that anthocyanidins (the aglycons of 439 
anthocyanins) have high affinity towards ERα. They showed that pelargonidin (6.8 μM) 440 
had the highest affinity among the assayed anthocyanidins followed by delphinidin (10.4 441 
μM) and cyanidin (12.2 μM) (Cornwell 2004). In a similar way Chalopin et al (2010) 442 
showed that the endothelium-dependent vasorelaxation of delphinidin and a red wine 443 
extract is mediated via ERα. With respect to ERα, the presence of up to 2-OH groups in the 444 
B-ring of the molecular structure decreased the affinity of the anthocyanins to the ERα 445 
(Fang 2001). In contrast, delphinidin-3-glucoside and gallic acid with 3-OH groups 446 
demonstrated the highest affinity for ERβ in our study.  447 
 448 
Study of the binding mode on ERβ and ERα: docking studies 449 
We carried out docking studies for the anthocyanidins listed in Table 5 (delphinidin, 450 
pelargonidin, peonidina, malvidin and cyanidin) and their metabolites (gallic and 451 
protocatechuic acids; see Figure 1 for chemical structures) in the ligand binding domains 452 
(LBD) of both ERα and ERβ. In general, docking predictions were in agreement with 453 
affinity data. 454 
Taking genistein (binding mode) as a reference, our purpose was to study whether the 455 
docking protocol was able to predict both the binding poses for anthocyanidins and any 456 
binding preference that could suggest selectivity. Regarding the binding poses, the most 457 
favourable poses corresponded to docked orientations where OH bonds between hydroxyl 458 
groups and His524 (ERβ His476) and Arg394-Glu353 (ERβ Arg346-Glu305) are the main 459 
interactions, anchoring the ligand within the LBD of ER. These interactions are crucial to 460 
give rise to a stable ligand-receptor complex that could account for the observed affinity. 461 
Regarding selectivity, no solutions were predicted for delphinidin by AutoDock when 462 
docked to ERα, while favourable binding orientations were found in ERβ (Figure 2). On the 463 
contrary, in the case of peonidin, only favourable poses were located in ERα (Figure 3). 464 
These results are in agreement with the experimental affinity values (Table 6), which show 465 
ERβ selectivity for delphinidin and ERα selectivity for peonidin. Our results are also in 466 
agreement with previous reports (Schmitt 1996). As mentioned above, it should be pointed 467 
out that delphinidin has 3-OH groups in the B-ring. However, for pelargonidin, similar 468 
binding results were predicted without meaningful differences. Also, affinity assays only 469 
exhibited a slight preference towards ERα. 470 
No binding poses were found for malvidin and cyanidin, in agreement with the absence of 471 
affinity, suggesting that these compounds are not suitable ER-ligands. 472 
In the case of phenolic acids, which are smaller molecules, all showed ability to bind to 473 
different regions of the LBD. Our computational efforts were then directed towards the 474 
study of the putative binding of two molecules within the LBD. AutoDock predicted that 475 
two units of both phenolic acids are able to interact simultaneously with the LBD, by 476 
adopting several orientations. Thus, we found that this hypothesis was possible from a 477 
theoretical perspective, since binding poses were found to reproduce the main interactions 478 
present in large ligands, justifying the antiproliferative effect shown in the MCF-7 cell 479 
model: hydrogen bonds between hydroxyl groups and His524 (ERβ His476) and Arg394-480 
Glu353 (ERβ Arg346-Glu305) (Figure 4). From the study of interactions and predicted 481 
binding energies, it can be concluded that gallic acid binds with higher affinity to both ERs, 482 
compared with protocatechuic acid. Regarding selectivity, similar binding energy values 483 
were predicted for both ERα/ERβ receptors. With these theoretical results, selectivity 484 
cannot be sighted. 485 
Our results suggest that gallic acid could potentially be considered as an 486 
enterophytoestrogen; a gut microflora-derived metabolite that can exhibit higher 487 
estrogenic/antiestrogenic activity than its corresponding precursor. 488 
Nevertheless, the fact that these polyphenols demonstrate affinity for the estrogen receptors 489 
and display agonist/antagonist effects may suggest that these compounds could act in target 490 
genes and in tissues where they could collaborate in the health promoting properties of 491 
anthocyanins. 492 
 493 
Concluding remark 494 
The mechanisms underlying the antiatherogenic effect of anthocyanins consumption is 495 
probably multifactorial. Our study suggests that the protective health effects of 496 
anthocyanins might not only be due to anthocyanins themselves, but also to their 497 
metabolites produced by action of the gut microflora. Both anthocyanins and their phenolic 498 
acid metabolites might play a role in decreasing vascular inflammatory markers, such as 499 
cytokines and adhesion and chemoattractant molecules. Despite observing a slight 500 
modulation of NO production by protocatechuic acid, the concentrations required to 501 
produce this effect do not fit with this being a potential mechanism of action for the 502 
antiatherogenic properties of anthocyanins. It might be the ability of anthocyanins and three 503 
of their metabolites to inhibit ACE activity which could decrease the expression of 504 
inflammatory markers and therefore improve endothelial function. On the other hand, some 505 
of the assayed metabolites have shown a relatively important affinity for ER α and β which 506 
regulate transcription of target genes, such as NF-kB. This affinity could also be implicated 507 
in atheromatosis. Overall, the concentrations of anthocyanins and their metabolites, as used 508 
in the present cell culture and in vitro assays mediating anti-inflammatory, anti-adhesive, 509 
anti- anti-estrogenic, and angiotensin-converting enzyme inhibitory activities were often 510 
manifold higher than those physiologically achievable (Vitaglione 2007). Further research, 511 
preferably in vivo, is necessary to determine if, and to what extent, anthocyanin metabolites 512 
play a role in the prevention of atherosclerosis in humans. 513 
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Figure 1. Chemical structure of the main anthocyanidins and the phenolic metabolites 707 
assayed. 708 
Figure 2. ERβ residues highlighted alongside docked delphinidin, viewed from the front of 709 
the binding pocket. 710 
Figure 3. Configuration of peonidin docked in the ERα binding site. ERα residues in the 711 
ligand binding domain are highlighted.  712 
Figure 4. Model of two docked molecules of gallic acid inside the ER ligand binding 713 
domain: hydrogen bonds between hydroxyl groups and His524 (ERβ His476) and Arg394-714 
Glu353 (ERβ Arg346-Glu305) are shown. 715 
  716 
717 
Table 1. Effect of protocatechuic acid on the inhibition of nitric oxide production in RAW 718 
264.7 macrophages. 719 
Protocatechuic (μM) Inhibition of NO 
production (%) 
 
 LPS 1μg/mL LPS 1μg/mL+IFN-γ 
1000U/mL 
25 16.2 ± 3.3
* 
4.3 ± 1.3
* 
50 21.3 ± 3.4
* 
6.1 ± 0.3
* 
100 27.4 ± 5.7
* 
12.7 ± 3.3
* 
 720 
Cells were pre-treated with protocatechuic acid for 3 h and then stimulated for 24 h with 721 
LPS (1 µg/ml) or LPS (1 µg/ml) + INF-γ (1000 U/ml). Data were compared to activated 722 
controls treated with LPS 1μg/mL (62.9 ± 20.2 nmol/mg protein) or LPS 1μg/mL + IFN-γ 723 
1000U/mL (101.1 ± 9.0 nmol/mg protein). Data derived from at least three independent 724 
experiments performed in triplicate and is expressed as means ± S.D. * indicates statistical 725 
significance: p<0.05 comparing the value with control. 726 
727 
Table 2. Effect of protocatechuic acid on nitric oxide inhibition in RAW 264.7 728 
macrophages using two different experimental conditions. 729 
Protocatechuic (μM) Inhibition of NO production (%) 
 LPS 1μg/mL LPS 1μg/mL+IFN-γ 
1000U/mL 
Pre-treated 2.4 ± 16.9 3.7 ± 3.3 
Co-treated 19.7 ± 7.5* 29.3 ± 4.1* 
 730 
Cells pre-treated with 10 μM protocatechuic acid for 3 h and then stimulated for 24 h with 731 
LPS (1 µg/ml) or LPS (1 µg/ml) + INF-γ (1000 U/ml) and cells co-incubated with 732 
protocatechuic acid and LPS (1 µg/ml) or LPS (1 µg/ml) + INF-γ (1000 U/ml) for 24 h. 733 
Data were compared to activated control. Experiments performed in triplicate and data are 734 
expressed as means ± S.D. * indicates statistical significance: p<0.05 comparing the value 735 
with control. 736 
737 
Table 3. Effect of gallic acid on MCP-1, ICAM-1 and VCAM-1 secretion in Ea.hy 926. 738 
Gallic acid (μM) MCP-1 (%) ICAM-1 (%) VCAM-1 
(%) 
0 100 100 100 
1 96.2 ± 5.0 94.5 ± 4.4 88.0 ± 38.3 
10 85.7 ± 3.1* 91.9 ± 0.6* 76.2 ± 13.7* 
50 81.2 ± 2.4* 88.6 ± 5.6 50.8 ± 5.9* 
100 78.9 ± 1.8* 79.9 ± 0.6* 41.2 ± 4.9* 
 739 
Cells were pre-treated with gallic acid (0, 1, 10, 50 and 100 μM) for 16 h and then activated 740 
6 h with TNF-α (10 ng/ml). Data were compared to TNF-α stimulated controls (not treated 741 
with gallic acid). Data were derive from three independent experiments performed in 742 
duplicated and are expressed as means ± S.D. * indicates statistical significance: p<0.05 743 
comparing the value with control. 744 
745 
Table 4. ACE-inhibitory activity of anthocyanins and phenolic acids. 746 
Sample IC50 (µM) 
Gallic acid 332.4 ± 40.1 
 Caffeic acid 157.3 ± 16.1 
157.3 ± 16.1 
 
Coumaric acid 504 2 31 5
504.2 ± 31.5 
04.36 
Malvidin-3-O-glucoside 83 9 5.1  
 Delphinidin-3-O-glucoside 65.  ± 4.0 
 Cyanidin-3-O-glucoside 70.8 ± 2.0 
 Pelargonidin-3-O-glucoside 77.7 ± 2.3 
 Peonidin-3-O-glucoside 104.6 ± 5.8 
 
 
 
 
 747 
IC50: concentration of compound needed to inhibit the original ACE activity by 50%. 748 
749 
Table 5. Relative affinity of anthocyanins and phenolic acids for ER α and ER β. 750 
 751 
Compound ERα IC50 (μM)* ERβ IC50 (μM)* 
Delphinidin-3-O-glucoside NA 63.2 ± 0.8 
Pelargonidin-3-O-glucoside 61.3 ± 0.7 93.0 ± 0.8 
Peonidin-3-O-glucoside 64.4 ± 0.9 NA 
Malvidin-3-O-glucoside NA NA 
Cyanidin-3-O-glucoside NA NA 
Gallic acid NA 100.3 ± 0.9 
Protocatechuic acid NA NA 
Syringic acid NA NA 
Vanillic acid NA NA 
 752 
*IC50 is defined as the concentration required to achieve 50% inhibition in the binding of 753 
[
3
H]-estradiol to the corresponding estrogen receptor (ER). NA, not achieve binding at the 754 
assayed concentration. IC50 values are shown as mean ± SD. 755 
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